Plasma exchange in thrombotic thrombocytopenic purpura
- PMID: 6541965
- PMCID: PMC1483661
Plasma exchange in thrombotic thrombocytopenic purpura
Abstract
Three patients were recently treated for thrombotic thrombocytopenic purpura (TTP). One presented with toxic shock syndrome; TTP developed but promptly responded to a regimen of antiplatelet agents, steroids and plasma exchange. In another the manifestations of TTP developed after presentation with hypertension and abdominal pain. This patient responded to a similar regimen but required extended treatment before remission could be maintained with medications alone. In the third patient the full TTP syndrome appeared after several days of plasma exchange treatment for hemolyticuremic syndrome. He did not respond. It is suggested that TTP may present in many forms initially, that microangiopathic hemolysis may be a late manifestation and that the optimal therapy is not known.
Similar articles
-
Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP.Haematologica. 1997 Jul-Aug;82(4):429-35. Haematologica. 1997. PMID: 9299856 Clinical Trial.
-
[Thrombotic thrombocytopenic purpura: report of seven cases].Ann Ital Med Int. 2005 Apr-Jun;20(2):108-12. Ann Ital Med Int. 2005. PMID: 16052844 Italian.
-
First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange.J Clin Apher. 2002;17(4):204-6. doi: 10.1002/jca.10037. J Clin Apher. 2002. PMID: 12494414 Review.
-
Plasma manipulation in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.Ann Med Interne (Paris). 1992;143 Suppl 1:19-26. Ann Med Interne (Paris). 1992. PMID: 1300882 Review.
-
Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center.J Clin Apher. 2004;19(3):119-24. doi: 10.1002/jca.20004. J Clin Apher. 2004. PMID: 15493057
Cited by
-
TTP: From empiricism for an enigmatic disease to targeted molecular therapies.Br J Haematol. 2022 Apr;197(2):156-170. doi: 10.1111/bjh.18040. Epub 2022 Feb 10. Br J Haematol. 2022. PMID: 35146746 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources